Trial Profile

A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SHR-A1921 (Primary)
Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Suzhou Suncadia Biopharmaceuticals

10 Sep 2024 Status changed from not yet recruiting to recruiting.
29 Mar 2024 Results (n=119) assessing Combined Parent and Payload Population Pharmacokinetic Modeling to Support Dose Recommendation of SHR-A1921 presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
19 Apr 2023 Results (As of Oct 21. 2022, n=38 )presented at the 114th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com